ReviewFrontiers in oncology2021
Repurposing Infectious Diseases Vaccines Against Cancer.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial.Journal for immunotherapy of cancer · 2023Trial
- Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot.Human vaccines & immunotherapeutics · 2026Review
- BCG in the fight against cancer: exploring its applications in diverse tumour types and future directions.Ecancermedicalscience · 2026Review
- Harnessing SARS-CoV-2 immunity to promote antitumor responses through intratumoral vaccination and adoptive transfer.Frontiers in immunology · 2026Article
- Engineered PCV2 VLPs for Antigen Delivery: A Platform for Next-Generation Veterinary Vaccines.Transboundary and emerging diseases · 2026Review
- Impact of Covid-19 Pandemic on Knowledge and Attitude of Nursing Students Regarding Vaccination and Vaccine Hesitancy in China: A Cross-Sectional Study.Health science reports · 2025Article
- Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice.Scientific reports · 2025Article
- Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer's defenses.Frontiers in immunology · 2025Review
- CanVaxKB: a web-based cancer vaccine knowledgebase.NAR cancer · 2024Article
- Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.Frontiers in immunology · 2024Review
- Flaviviruses in AntiTumor Therapy.Viruses · 2023Review
- Pleiotropic Effects of Influenza Vaccination.Vaccines · 2023Review
- Cholera vaccine clinical trials: A cross-sectional analysis of clinical trials registries.Human vaccines & immunotherapeutics · 2023Article
- Review
- Combination Therapy for the Treatment of Shingles with an Immunostimulatory Vaccine Virus and Acyclovir.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future.Current pharmaceutical biotechnology · 2023Review
- Resolution of recalcitrant verruca following Moderna COVID-19 vaccination in a person with HIV.JAAD case reports · 2023Article
- Unlocking therapeutic potential: integration of drug repurposing and immunotherapy for various disease targeting.American journal of translational research · 2023Review
- Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections.Frontiers in immunology · 2022Article
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines used to prevent infections have long been known to stimulate immune responses to cancer as illustrated by the approval of the Bacillus Calmette-Guérin (BCG) vaccine to treat bladder cancer since the 1970s. The recent approval of immunotherapies has rejuvenated this research area with reports of anti-tumor responses with existing infectious diseases vaccines used as such, either alone or in combination with immune checkpoint inhibitors. Here, we have reviewed and summarized research activities using approved vaccines to treat cancer. Data supporting a cancer therapeutic use was found for 16 vaccines. For 10 (BCG, diphtheria, tetanus, human papillomavirus, influenza, measles, pneumococcus, smallpox, typhoid and varicella-zoster), clinical trials have been conducted or are ongoing. Within the remaining 6, preclinical evidence supports further evaluation of the rotavirus, yellow fever and pertussis vaccine in carefully designed clinical trials. The mechanistic evidence for the cholera vaccine, combined with the observational data in colorectal cancer, is also supportive of clinical translation. There is limited data for the hepatitis B and mumps vaccine (without measles vaccine). Four findings are worth highlighting: the superiority of intravesical typhoid vaccine instillations over BCG in a preclinical bladder cancer model, which is now the subject of a phase I trial; the perioperative use of the influenza vaccine to limit and prevent the natural killer cell dysfunction induced by cancer surgery; objective responses following intratumoral injections of measles vaccine in cutaneous T-cell lymphoma; objective responses induced by human papillomavirus vaccine in cutaneous squamous cell carcinoma. All vaccines are intended to induce or improve an anti-tumor (immune) response. In addition to the biological and immunological mechanisms that vary between vaccines, the mode of administration and sequence with other (immuno-)therapies warrant more attention in future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.